Abstract Library

#4506 Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. streptozocin-based chemotherapies (STZ-BC) as first-line (1L) treatment for advanced grade 2/3 (G2/G3) pancreatic NETs (pNETs)

Introduction: The NETTER-2 trial showed improved progression-free survival (PFS) with 1L 177Lu-DOTATATE vs. high dose octreotide in advanced G2/G3 pNETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments, such as STZ-BC, hence indirect comparisons need to be conducted.

Conference:

Presenting Author: Navalkissoor S

Authors: Navalkissoor S, Capdevila J, Deshayes E, Gerard L, Srirajaskanthan R,

Keywords: pancreatic neuroendocrine tumour, [177lu]lu-dotatate, streptozocin, 5-fluorouracil, matching adjusted indirect comparison,

#4504 Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. CAPTEM as first-line (1L) treatment for advanced grade 3 (G3) gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Introduction: The NETTER-2 trial showed a significant progression-free survival (PFS) benefit with 1L 177Lu-DOTATATE vs. high dose octreotide for patients with advanced G2/G3 GEP-NETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments for patients with G3 GEP-NETs, such as capecitabine + temozolomide (CAPTEM), hence indirect comparisons need to be conducted.

Conference:

Presenting Author: Deshayes E

Authors: Deshayes E, Capdevila J, Gerard L, Navalkissoor S, Srirajaskanthan R,

Keywords: gastroenteropancreatic neuroendocrine tumour, [177lu]lu-dotatate, capecitabine, temozolomide, matching adjusted indirect comparison,

#3932 Artisan: Prospective phase II trial of TheraSphere Selective Internal Radiation Therapy (SIRT) for liver metastases in neuroendocrine tumors (NETs)

Introduction: The liver is the commonest site of metastases and is an independent predictor of poor outcome. SIRT allows delivery of high dose radiation to liver metastases and has shown promise in the management of NETs. We determined the safety and efficacy of SIRT in those with inoperable liver metastases in a prospective study.

Conference:

Presenting Author: Ahmed Q

Authors: Ahmed Q, Doumanoglou N, Evans J, Martinez M, Ward C,

Keywords: radioembolization, carcinoid, neuroendocrine, metastases,

#3799 High-dose somatostatin analogues’ effects on glycolipid metabolism in patients with neuroendocrine tumors

Introduction: Somatostatin analogues (SSAs), octreotide and lanreotide, represent the cornerstone medical therapy of both sporadic and hereditary G1-G2 neuroendocrine tumors (NETs). Changes in glucose metabolism have been shown to occur during standard-dose SSA therapy, but no changes during high-dose therapy have been evaluated.

Conference:

Presenting Author:

Authors: Liccardi A, Minotta R, Cannavale G, Benevento E, Modica R,

Keywords: neuroendocrine tumor, somatostatin analogues, lipid, hyperglycaemia, high dose SSA, glycolipid metabolism,

#3764 Therapeutic response of ACTH-dependent ectopic Cushing's syndrome to low doses of osilodrostat

Introduction: Cushing's disease (CD) is the main cause of ACTH-dependent Cushing's syndrome (ACTH-CS). In 5–15% of cases, ACTH/CRH production is ectopic and is caused by neuroendocrine tumors of the lung, thymus, or pancreas, medullary thyroid carcinoma, and pheochromocytoma. Diagnostic imaging can locate the primary tumor; however, between 8-22% the cause is unknown. The FDA approved Osilodrostat for the treatment of inoperable or refractory CD, its use in high doses in patients with ectopic CS has been reported.

Conference:

Presenting Author:

Authors: González Devia D, Florez-Romero A, Rojas-Camacho J, Herrera Almario G, Jimenez Hakim E,

Keywords: ACTH-dependent Cushing's syndrome, Osilodrostat, Adrenal steroidogenesis inhibitors, Ectopic ACTH Cushing´s syndrome,